Skip to Content
Merck
  • Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis.

Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (2007-04-19)
Eiichi Uchio, Yuki Itoh, Kazuaki Kadonosono
ABSTRACT

We evaluated the efficacy and safety of long-term management of patients with vernal keratoconjunctivitis (VKC) with bromfenac sodium eye drops in combination with corticosteroids and anti-allergic eye drops. Twenty-two patients with VKC were randomly assigned to receive two test eye drops, either bromfenac sodium 0.1% (group A) or placebo eye drops (normal saline; group B) for a mean observation period of 20.9 months. Topical corticosteroids and mast cell stabilizers were continued during the observation period. The mean 2-year recurrence rate was 90.9% in group A and 11.3% in group B, with a significant difference. No serious side effect was observed in group A. These results suggest that bromfenac sodium eye drops can be used as baseline local treatment in patients with VKC.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Bromfenac sodium, ≥98% (HPLC)
SKU
Pack Size
Availability
Price
Quantity